Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Novel Laboratories, Inc. d.b.a Lupin Somerset
483
•Novel Laboratories, Inc. d.b.a Lupin Somerset•March 30, 2022

Novel Laboratories, Inc. d.b.a Lupin Somerset – FDA 483, Mar 30, 2022

Record Details

The FDA Form 483 details numerous deficiencies observed during an inspection of a drug manufacturing facility. The facility failed to thoroughly review unexplained discrepancies and out-of-specification batches. The qualification of a contract packager for (b)(4) Tablets was not documented, and SAP discrepancy investigations were not evaluated within the Quality system. Procedures for raw data document issuance and reconciliation were absent. Scientific justification for not performing microbial testing on (b)(4) Tablets and (b)(4) Capsules was not provided. Change controls for multiple documents lacked sufficient detail for adequate evaluation. The implementation of 100% cleaning verification on non-dedicated equipment was not handled through a Quality System. Procedures for handling drug product complaints were not written or followed, and employees lacked required training. Equipment cleaning and maintenance procedures were deficient in detail, and cleaning gaps of up to 14 days were noted for liquid manufacturing tanks. A logbook indicated cleaning started after manufacturing on 2/24/2022, but the walkthrough was on 3/7/2022. Supporting documentation for method validation (MVP-SOAP-CLN-LC and MVR-SOAP-CLN-LC from 2007) was unavailable. Written procedures for equipment cleaning and maintenance were not established or followed. Equipment design was not appropriate for intended use, and a 100% check-weigher (ID No. 2017) was not adequately qualified or calibrated

Company
Novel Laboratories, Inc. d.b.a Lupin Somerset
Inspection date
March 30, 2022
Office
New Jersey District Office
People
  • Adetutu M. Gidado
  • Ko U. Min (Consumer Safety Officer at FDA U.S. Food and Drug Administration)
  • Sandra A. Boyd (Drug National Expert)
View Company Profile

ID · d2442992-2045-48b7-a2c8-31301ba9b7c1

Violation Codes10
21 U.S.C. 351(h)21 CFR 21021 CFR 21121 CFR 211.68(b)21 CFR 211.100(b)21 CFR 211.67(b)21 CFR 211.110(a)21 CFR 211.19821 CFR 211.13021 CFR 211.160

Full citation text and observation details available on the Dashboard.

Other documents for Novel Laboratories, Inc. d.b.a Lupin Somerset
  • 483 - 2026-04-17April 17, 2026
  • 483 - 2025-10-10October 10, 2025
  • 483 - 2023-01-13January 13, 2023
  • WARNING_LETTER - 2020-11-05November 5, 2020
  • 483 - 2020-11-05November 5, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novel Laboratories, Inc. d.b.a Lupin Somerset
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.